Please login to the form below
teclistamab
This page shows the latest teclistamab news and features for those working in and with pharma, biotech and healthcare.
Janssen’s Tecvayli granted FDA approval for multiple myeloma
Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Tecvayli (teclistamab-cqyv) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with ... Multiple myeloma is a life-threatening
Latest news
-
Janssen’s teclistamab granted conditional marketing authorisation by EC
The decision makes teclistamab the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma. ... Teclistamab is an important addition to our multiple myeloma portfolio. We are continuing to.
-
Janssen submits marketing authorisation to EMA for teclistamab
Janssen – a branch of Johnson &Johnson – has announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for approval of teclistamab – a drug used to treat ... Janssen’s application to the EMA
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
